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Background: Extramural venous invasion (EMVI) is a poor prognostic factor in rectal cancer and identified on magnetic resonance
imaging (MRI) (mrEMVI). The clinical relevance of improvement in mrEMVI following neoadjuvant therapy is unknown. This study
aimed to demonstrate that regression of mrEMVI following neoadjuvant chemoradiotherapy (CRT) results in improved outcomes
and mrEMVI can be used as an imaging biomarker
Methods: Retrospective analysis of prospectively collected data was conducted examining the staging and post-treatment MRIs
of patients who had presented with EMVI-positive rectal cancer. All patients had undergone neoadjuvant CRT and curative
surgery. Changes in mrEMVI were graded with a new MRI-based TRG scale–mr-vTRG; and related to disease-free survival (DFS).
The study fulfilled Reporting Recommendations for Tumour Marker Prognostic Studies criteria for biomarkers.
Results: Sixty-two patients were included. Thirty-five patients showed more than 50% fibrosis of mrEMVI (mr-vTRG 1-3); 3-year DFS
87.8% and 9% recurrence. Twenty-seven patients showed less than 50% fibrosis (mr-vTRG 4-5); 3-year DFS 45.8% with 44%
recurrence – Po0.0001. On multivariate Cox-regression, only mr-vTRG 4-5 increased risk of disease recurrence – HR¼ 5.748.
Conclusion: Patients in whom there has been a significant response of EMVI to CRT show improved DFS. Those patients with poor
response should be considered for intensive treatment. As an imaging biomarker in rectal cancer, mrEMVI can be used.
Extramural venous invasion (EMVI) is defined as the presence of
tumour cells in the vasculature beyond the muscularis propria. Its
manifestation produces locally advanced tumours, which penetrate
more deeply into the mesorectum and beyond; and is a known
marker of poor survival outcomes and disease recurrence (Talbot
et al, 1980; Knudsen et al, 1983; Freedman et al, 1984). Despite its
association with poor prognosis, it is not treated independently or
with consistency from other T3 tumours with regard to oncological
treatment decisions.
Traditionally, EMVI has been detected on histopathological
analysis of surgical resection specimens (Figure 1). However,
relying on pathological identification has been shown to result in
substantial under-reporting (Messenger et al, 2012); a limitation
of historical studies that could account for the large range of
incidence of venous invasion (8–81%) cited in the literature
(Brown, 1938; Seefeld and Bargen, 1943; Madison et al, 1954;
Dukes and Bussey, 1958; Talbot et al, 1980; Rich et al, 1983;
Jass et al, 1986; Sasaki et al, 1987; Minsky et al, 1988). The most
likely reason for this is the lack of a consistent pathological
definition and technique in reporting venous invasion, particularly
the lack of use of elastic tissue stains, which can help distinguish
lymphatic from venous invasion (Messenger et al, 2012).
Recent reports have shown that EMVI can be readily identified
on magnetic resonance imaging (MRI) – mrEMVI; both before and
after neoadjuvant therapy (Mercury Study Group, 2006; Smith
et al, 2008a, b; Patel et al, 2011). Indeed, MRI may be superior to
routine histopathology analysis of the resection specimens
in identifying EMVI, particularly if it is not specifically sought or
*Correspondence: M Chand; E-mail: mans001@aol.com or manish.chand@rmh.nhs.uk
Received 4 June 2013; revised 8 September 2013; accepted 11 September 2013; published online 3 December 2013
& 2014 Cancer Research UK. All rights reserved 0007 – 0920/14
FULL PAPER
Keywords: rectal cancer; venous invasion; EMVI; neoadjuvant chemoradiotherapy; follow-up; recurrence
British Journal of Cancer (2014) 110, 19–25 | doi: 10.1038/bjc.2013.603
www.bjcancer.com |DOI:10.1038/bjc.2013.603 19
if technique is limited (Messenger et al, 2012). Magnetic resonance
imaging has the advantage of demonstrating vascular anatomy
in vivo and thus tumour invasion can be readily identified.
Therefore, recording the presence or absence of mrEMVI has
become routine in our institution since first described and
validated (Smith et al, 2008a; Figure 2).
Extramural venous invasion may have a role in pre-operative
risk-stratification and further, influence decisions with regard to
adjuvant chemotherapy or more intensive neoadjuvant treatment.
Extramural venous invasion responds to neoadjuvant chemoradia-
tion therapy (CRT) by causing vessel fibrosis which can be detected
on MRI (Figure 3). These radiological changes may result in
improved survival outcomes. The prognostic effect of MRI-
detected EMVI (mrEMVI) has previously been examined (Smith
et al, 2008a); however, the effect of CRT on the morphology and
subsequent clinical outcomes are unknown. The potential to grade
regression of EMVI following neoadjuvant treatment means that it
could be used as an imaging biomarker to measure effectiveness of
such treatment.
This study aimed to demonstrate that improvement in the
degree of mrEMVI following neoadjuvant CRT results in improved
survival outcomes. Further, by relating the radiological improve-
ment in EMVI to better outcomes in terms of disease recurrence
and time to recurrence this would suggest that mrEMVI could be
used as a predictive imaging biomarker.
MATERIALS AND METHODS
A retrospective analysis of prospectively collected data was
conducted examining the staging and post-treatment MRI scans
of patients who had presented with primary rectal cancer and MRI
evidence of EMVI between January 2006 and January 2012.
Patients eligibility included mrEMVI on baseline staging imaging
followed by treatment with neo-adjuvant CRT followed by curative
‘total mesorectal excision’ (Heald and Ryall, 1986) surgery as
decided by the specialist multidisciplinary team. All patients were
offered and underwent adjuvant chemotherapy after surgery.
Patients below the age of 18 years and those with synchronous
tumours or metastases on presentation were excluded. The study
fulfilled the relevant Reporting Recommendations for Tumour
Marker Prognostic Studies (REMARK) criteria (Mcshane et al,
2005).
Chemoradiotherapy regime. All patients underwent long-course
preoperative therapy for MRI-identified potential circumferential
resection margin (CRM) involvement and for MRI-predicted T3
tumours with adverse features, such as extramural venous invasion,
extramural spread greater than 5mm, or N2 disease. Radiotherapy
consisted of 45–54Gy delivered to the primary tumour and
pelvic lymph nodes at risk. Concurrent CRT was given with a
Figure 2. MRI showing radiological features of EMVI.
Figure 3. MRI showing EMVI response to chemoradiation.
Figure 1. Histopathological detection of EMVI (H and E stain).
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fluoropyrimidine. Treatment response was assessed by MRI and
surgery was undertaken at 6–8 weeks after CRT.
Post-operative chemotherapy regime. Patients who are scheduled
for adjuvant chemotherapy are given combination chemotherapy.
The policy of our institution is to routinely give patients with stage
III disease adjuvant chemotherapy in addition to patients who
demonstrate high-risk features on baseline imaging and therefore
require pre-operative therapy. For patients with stage II disease
following pre-operative treatment, a discussion is had between
patient and oncologist regarding the benefits of further adjuvant
treatment.
Twelve weeks of adjuvant chemotherapy were administered.
Oxaliplatin (130mgm 2) was delivered every 3 weeks, and
capecitabine was administered orally at a dose of 2000mgm 2
per day divided into two split doses for 14 days followed by 7 days
of rest repeated every 3 weeks. Dose adjustment was made in the
event of toxicity.
Radiological mr-staging. The local policy of our institution is for
all patients with rectal cancer to routinely undergo local staging
with MRI and for those patients who have CRT to have further
MRI scans to assess treatment response. Each patient underwent a
minimum of two MRI scans, before and after CRT, which were
available for review. Where patients had undergone more than one
post-CRT MRI scan, the most recent scan immediately before
surgery was reviewed for the purposes of analysis. A senior
radiologist (GB) blinded to the clinical data reviewed all MRI
images for staging before and after CRT.
mrT-stage was categorised into either ‘good’ or ‘poor’ based on
the extent of tumour spread into the mesorectum. ‘T-good’
included all tumours staged as T3b or better, whereas T3c or worse
were recorded ‘T-poor’ (Appendix 1 – T3 sub-staging). mrN stage
was categorised as either positive or negative, and mrCRM was
considered positive if the tumour edge was within 1mm of the
CRM. These characteristics were recorded pre-treatment and post-
treatment (mr- and ymr-stage).
ymr-EMVI status was recorded as either positive or negative –
positive status was a score of 3 or 4 on the MRI-EMVI grading
system (Table 1). Further MRI assessment for the extent and site of
EMVI was recorded in addition to the degree of regression. This
was categorised as large-vessel mrEMVI if tumour invasion was
identified into superior, middle or inferior rectal veins; or small-
vessel disease if mrEMVI was seen into non-anatomical vessels. A
novel EMVI-specific regression grading scale (mr-vTRG) was used
to categorise the degree of EMVI regression. The criteria for the
mr-vTRG score is shown in Table 2.The treatment response was
measured by the degree of fibrosis present in the extramural
vasculature.
Fibrosis in contradistinction to tumour is characterised on MRI
as dense low (dark/black) signal intensity rather than the nodular
intermediate (relatively brighter/grey) signal intensity of tumour.
This is best seen on post-CRT T2-weighted MRI, the areas of
fibrosis have very low signal intensity, whereas areas of residual
tumour have intermediate signal intensity. The signal intensity of
fibrosis is similar to that of the muscularis propria, and signal
intensity of residual tumour is similar to that of baseline tumour.
Histopathology staging. Final histopathology staging (yp-stage)
included T-stage, N-stage, EMVI status and CRM involvement.
Statistical analysis. The response of EMVI to CRT was measured
using the mr-vTRG scale as described above. For the purposes of
analysis, patients were categorised into two groups based on
whether there had been more or less than 50% fibrosis seen within
the lumen of the affected vessels – mr-vTRG1-3 (good mr-venous
responder) and mr-vTRG4-5 (poor mr venous responder). Survival
outcomes included recurrence rates, site of recurrences, and 3-year
disease-free survival (DFS). Differences in staging characteristics
between groups were analysed using Fisher’s exact test and
Chi-squared, where appropriate. Survival curves for DFS were
calculated using the Kaplan–Meier product limit method; differ-
ences between survival curves for mr-vTRG levels were tested for
significance using the Mantel-Cox log-rank test. An event was
radiological or pathological detection of recurrent/metastatic
disease or death from any cause. Time to event was recorded
from the start of treatment date. Multivariate analysis was
performed using Cox regression for time to recurrence. A P-value
of o0.05 was considered significant. Hazard ratios were recorded
with 95% confidence intervals. Statistical analysis was performed
on Excel and SPSS 19.0 (Chicago, IL, USA).
RESULTS
A total of 88 patients met the inclusion criteria of which 62 were
included for analysis. Reasons for exclusion were metastatic disease
on presentation, incomplete neoadjuvant treatment and EMVI not
evident on MRI review. Twenty-one patients were female and
forty-one male. The median age was 68 (range 28–87) years.
Baseline mr-staging. The baseline MRI staging characteristics are
shown in Table 3. Sixty patients (97%) were staged as mrT-poor
and forty-four patients (71%) also had MR-defined nodal disease at
the time of diagnosis. In all 62 patients, mrEMVI was present; of
these, 50 patients (81%) had evidence of large-vessel mrEMVI. The
height of the lower edge of the tumour from the anal verge was
measured on MRI for each patient – 21 low rectal (0–5 cm); 15
mid-rectal (6–10 cm) and 26 upper rectal (410 cm). The CRM was
considered threatened on MRI if the tumour margin spread to
within 1mm – same as histopathology criteria. Thirty-one patients
(50%) had a positive mrCRM.
Table 1. MRI characteristics of EMVI (mrEMVI)
MRI
score
Morphology features on MRI MRI status
0 Pattern of tumour extension through the rectal
wall is not nodular; no adjacent vessels
Negative
1 Minimal extramural stranding; no adjacent
vessels
Negative
2 Stranding in proximity of vessels but no tumour
signal in normal calibre lumen
Negative
3 Intermediate signal in lumen of vessels; slight
vessel expansion
Positive
4 Irregular vessel contour; definite tumour signal Positive
Abbreviations: EMVI¼ extramural venous invasion; MRI¼magnetic resonance imaging;
mrEMVI¼MRI-defined EMVI.
Table 2. mr-vTRG scale
mr-vTRG score Post-treatment mrEMVI features
1 Tumour signal replaced by vessel fibrosis
2 50–75% fibrosis of tumour signal
3 25–49% fibrosis of tumour signal
4 Less than 25% fibrosis of tumour signal
5 Minimal fibrosis of tumour signal within lumen
Abbreviation: mrEMVI¼ magnetic resonance imaging-defined extramural venous invasion.
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Post-treatment ymr-staging
ymr-Extramural venous invasion. The post-treatment MRI
staging characteristics can be seen in Table 3. Thirty-five patients
(56%) had more than 50% fibrosis of EMVI following CRT
(‘good venous reposnders’). This included 12 patients where there
was complete fibrosis of EMVI (mr-vTRG1), which is considered
to be a change in EMVI status from positive to negative. Twenty-
seven patients (44%) demonstrated less than 50% fibrosis of EMVI
(‘poor venous responders’).
In the good venous responder, 20 of 35 patients showed
evidence of large-vessel EMVI; 2 patients had small vessel disease
and 12 patients showed no evidence of EMVI. In the poor venous
responders, 26 of 27 patients had large-vessel EMVI and only 1
patient with small-vessel disease.
Other staging characteristics. Following CRT, 13 of 35 (37%)
patients were now staged as T-poor; 11 patients had nodal disease
(31%); and 5 patients (14%) showed that the CRM was still
threatened or involved in the good venous responders. Of the 27
poor venous responders, 26 were still T-poor (96%), 18 (67%) had
nodal disease and 17 (63%) had an involved CRM.
Histopathology staging. The post-treatment MRI staging char-
acteristics can be seen in Table 4. The majority of the good venous
reposnders were staged as ypT3 (17/35). One patient had a
pathological complete response with no residual tumour found;
twelve patients were staged as ypT2 and five patients were ypT4.
For nodal staging, 11 patients were node-negative and 24 patients
had N1/N2 disease. The CRM was clear of tumour in all patients.
In the poor venous responders group, one patient had a
pathological complete response and there was one patient staged as
ypT2. Twenty-two patients had ypT3 stage and three patients
had ypT4. Fourteen patients had node-negative disease,
whereas thirteen patients had N1/N2 disease. Two patients had a
positive CRM.
Survival analysis. Only three patients (9%) developed recurrence
from the good venous responders – two hepatic and one local
recurrence. Three-year DFS was 87.8%. In comparison, 12 patients
(44%) developed disease recurrence from the poor venous
responders, with the majority being hepatic metastases – 7 hepatic,
3 pulmonary and 2 local. Three-year DFS was 45.8% (Graph 1). A
Mantel-Cox log-rank test comparing survival showed a statistically
significant difference – P¼ 0.013.
On multivariate analysis of specific patient and tumour
characteristics using Cox regression, only regression of EMVI by
more than 50% (mr-vTRG1-3) was shown to be significant for
improved DFS and recurrence – P¼ 0.013. The hazard ratio of a
patient developing recurrence following CRT and surgery if
there was less than 50% fibrosis of EMVI was 5.748 (95% CI:
1.442–22.905).
DISCUSSION
Extramural venous invasion is known to be a marker of poor
prognosis (Talbot et al, 1980; Knudsen et al, 1983; Freedman et al,
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Graph 1. Kaplan–Meier curves for disease-free survival for patients
mr-vTRG 1-3 and mr-vTRG 4-5.
Table 3. Post-CRT MRI characteristics mr-vTRG 1-3 and mr-vTRG 4-5
Post-CRT
Staging
characteristic
Baseline
staging
Mr-vTRG
1-3
Mr-vTRG
4-5 P-value
mrT-stage
Good (mrT1-T3b) 60 22 1 o0.05
Poor (4mrT3b) 2 13 26
mrN stage
0 18 24 9 o0.05
1/2 44 11 18
EMVI vessel type
No evidence 0 12 0 40.05
(Small and
large
vessel)
Small vessel 12 3 1
Large vessel 50 20 26
mrCRM status
Negative 31 30 10 o0.05
Positive 31 5 17
Abbreviations: CRM¼ circumferential resection margin; CRT¼ chemoradiotherapy; EMVI¼
extramural venous invasion; MRI¼magnetic resonance imaging.
Table 4. Histopathology staging following surgery for mr-vTRG 1-3 or mr-
vTRG 4-5
No of patients
Staging characteristic Mr-vTRG 1-3 Mr-vTRG 4-5 P-value
ypT stage
PCR 1 1 o0.05
T2 12 1
T3 17 22
T4 5 3
ypN stage
0 24 13 0.12
1/2 11 14
ypCRM status
Negative 35 25 NA
Positive 0 2
Abbreviations: CRM¼ circumferential resection margin; NA¼ not applicable.
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1984). Extramural venous invasion is seen on MRI as a serpiginous
extension of tumour signal within a vascular structure. This is best
identified on T2-weighted images where the characteristic signal
and morphology differentiates it from nodal disease (Smith et al,
2008b). It is accurately detected on MRI (mrEMVI) correlating
with histopathology and allows for a more accurate estimation of
the true prevalence of EMVI in rectal cancer – approximately 40%
(Mercury Study Group, 2006; Smith et al, 2008a, b; Taylor et al,
2011b). This can be seen in Table 5.
This study has shown that good regression of mrEMVI with
more than 50% fibrosis is associated with significant improvement
in DFS, independent of final pathological staging (T-stage, nodal
status and CRM status). This finding was seen in 56% of patients
initially presenting with mrEMVI. Three-year DFS was only 45.8%
when there was less than 50% fibrosis (poor venous responders)
compared with 87.8% in good venous responders. In addition, the
recurrence rates were 9% for good mrEMVI vs 44% for poor
mrEMVI responders. This is the first study to specifically stratify
the tumour regression grade of EMVI following neoadjuvant
treatment using REMARK criteria for investigating imaging
biomarkers. These results would suggest that mrEMVI could be
used as a predictive imaging biomarker and that it is worthwhile
targeting patients with mrEMVI for further oncological treatment
such as neo-adjuvant chemotherapy rather than just chemo-
sensitisation to elicit further downstaging of mrEMVI, as those
patients showing a significant degree of fibrosis of mrEMVI have
improved survival outcomes.
Increasingly, using detailed MRI assessment enables more
effective risk and therefore therapeutic stratification early in the
patient treatment pathway (Mercury Study Group, 2006; Shihab
et al, 2011; Taylor et al, 2011a). The most important recognised
factors that influence neoadjuvant treatment are depth of tumour
penetration and, in particular, the extent of spread into the
mesorectum and beyond (T3-sub-stage and T4), and proximity of
the tumour edge to the CRM (Shihab et al, 2011; Taylor et al,
2011c). The response to neoadjuvant treatment can be measured
radiologically and histopathologically by the use of tumour
regression grades (Mandard et al, 1994; Suarez et al, 2008). The
regression grading enables an assessment of response in terms of
cytological changes and stromal changes including fibrosis, which
have been show to correlate well against outcomes (Rullier et al,
2001; Patel et al, 2011). Understanding the tumour response to
treatment pre-operatively with mrTRG scores has the advantage of
ensuring that surgery is oncologically successful and that further
intensive treatment may be offered to those patients who have not
shown an adequate response. However, both these scoring systems
do not specifically account for the effect of treatment on MRI
extramural venous invasion.
The consistent depiction on MRI of the larger veins such as the
superior and inferior rectal veins aids identifying the type and size
of vessel involved. Magnetic resonance imaging is therefore more
accurate in identifying large-vessel EMVI than smaller-vessel
disease (Smith et al, 2008a). We observed that the majority of
patients had large-vessel disease initially and where there was less
than 50% fibrosis of EMVI large-vessel disease predominated. This
confirms the importance, first shown by Talbot, of large-vessel
disease over smaller vessel (Talbot et al, 1981). Although small-
vessel EMVI may be more difficult to identify both radiologically
and histopathologically, it may in fact be of little clinical
consequence.
Following CRT, 38 patients showed more than 50% fibrosis
(mr-vTRG score of 1–3). Interestingly, of these 38 patients, 12
patients showed complete regression of mrEMVI and would be
reported as EMVI-negative on MRI – no evidence of EMVI.
Only one patient who had become mrEMVI-negative developed a
recurrence – hepatic metastases. There was also improvement in all
other prognostic factors as one would expect. As the study cohort
all underwent CRT, it is, by definition, a high-risk group of
patients. This can be seen by the baseline staging characteristics,
which show that almost all patients were staged as T-poor. In our
institution, not all T3 patients are universally irradiated and nodal
disease alone is not an indication for neo-adjuvant therapy. In the
mr-vTRG 1-3 group, the majority of patients was staged T3 but the
CRM was negative in all patients. Although there were a few
patients who were radiologically staged to have CRM involvement
following CRT on MRI, this information would have been known
to the surgeon allowing them to make appropriate surgical
decisions to ensure a clear margin. In the poor venous responders,
T3 tumours predominated and the CRM was involved in 3 patients
out of 28. More than half of patients still had nodal disease,
although this was not statistically relevant difference between the
groups. Further, on multivariate analysis, nodal disease was not a
significant factor and only mr-vTRG grade was significant.
These results suggest that EMVI regression is a prognostic
indicator for disease recurrence in addition to being predictive as
well. Patients who show little fibrosis of EMVI following CRT are
more likely to develop metastatic disease. The hazard ratio of 5.748
is significant and suggests that if patients show minimal regression
of EMVI following standard CRT that more intensive
pre-operative chemotherapy to further treat EMVI may improve
disease recurrence. These patients are at risk of developing
metastases and should be considered for aggressive therapy pre-
or post-operatively. This also raises the issue of more frequent
follow-up as currently there is no universal consensus on rectal
cancer surveillance after curative surgery. Although patients who
are enrolled in trials have a defined follow-up strategy, the timing
of imaging, serum CEA and colonoscopy varies from centre to
centre. Patients who are identified as high risk of metastatic disease
should be considered for more frequent follow-up, and in
particular more frequent liver imaging.
Table 5. Multivariate analysis of prognostic factors for disease-free
survival following neoadjuvant chemoradiation and TME surgery
Variable Hazard ratio 95% CI P-value
Sex
Female 1.000 0.527–4.149 0.458
Male 1.479
Height from anal verge (cm)
45 1.000 0.248–1.620 0.341
o5 0.634
EMVI regression
mrTRG 1-3 1.000 1.442–22.905 0.013
mrTRG 4-5 5.748
ypT stage
T3b or better 1.000 0.067–1.052 0.059
T3c or worse 0.265
ypN stage
N0 1.000 0.891–5.710 0.086
N1/2 2.255
ypCRM status
Negative 1.000 0.136–10.496 0.871
Positive 1.197
Abbreviations: CI¼ confidence interval; CRM¼ circumferential resection margin;
EMVI¼extramural venous invasion; TME¼ total mesorectal excision.
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One of the perceived limitations of this study is the use of a
specialist gastrointestinal radiologist to stage the MRI scans. It is
not always possible for patients’ imaging studies to be reported by
specialist radiologists and sub-specialisation has not been accepted
in the United Kingdom as yet. However, it has been previously
shown in the Mercury Study that technique and assessment of MRI
can be standardised, particularly when a specific proforma-based
system is adopted (Taylor et al, 2008, 2010). Further, this is a
retrospective analysis, however, the data collected was done so
from routine undertaken proforma reports, which mandate all the
MRI staging assessment data described in this paper.
CONCLUSION
Neoadjuvant therapy is known to improve survival outcomes and
downstage disease in terms of depth of tumour spread, regional
lymph node and CRM involvement. There have been no studies of
the effect of CRT on EMVI in terms of morphological change or
effect on survival outcomes. This is the first study to quantify the
radiological changes, which occur in EMVI following CRT and
how they relate to survival outcomes. Patients in whom there has
been more than 50% fibrosis and regression of EMVI show
significant improvement in DFS. In patients where there has been
less than 50% regression, consideration should be made for
additional neoadjuvant therapy. The regression and fibrotic
changes in EMVI following CRT are identifiable on MRI and by
showing that mrEMVI treatment response correlates with
improvement in disease recurrence, we suggest that it has a role
as a predictive imaging biomarker.
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APPENDIX 1
Table A1. T3 sub-stage classification
T-stage Depth of extramural spread of tumour edge into the
mesorectum (mm)
T3a o1.00
T3b 1.01–5.00
T3c 5.01–15.00
T3d 415.00
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